Pharmaniaga Bhd marked its entrance into the vaccine international market by successfully exporting the first batch of Sinovac filled and finished COVID-19 vaccine to Myanmar, manufactured by its wholly-owned subsidiary European Union certified high-tech plant, Pharmaniaga LifeScience Sdn Bhd (PLS).
In Myanmar, the Sinovac COVID-19 vaccine will be marketed by Hemas Mandalar Pharmaceuticals Ltd (Hemas Mandalar), a Myanmar-based pharmaceutical company, which has placed an initial order of 200,000 doses of filled and finished Sinovac COVID-19 vaccine from Pharmaniaga.
Recently, both companies have signed a Memorandum of Collaboration for Pharmaniaga to supply Sinovac COVID-19 vaccine to two private hospitals owned by Hemas Mandalar in Yangon. The delivery was made upon approval by Myanmar’s Food and Drugs Authority.
Pharmaniaga Group Managing Director Datuk Zulkarnain said the collaboration with Hemas Mandalar would help to accelerate Myanmar’s private market vaccination programme.
As of October 31, 2021, Myanmar is reported to have 13% of its population completely vaccinated against the COVID-19 virus1.
“The total supply of 200,000 doses of vaccine will be delivered in a few stages starting November 13.
“This opportunity to collaborate with one of the leading pharmaceuticals companies in Myanmar will hopefully further strengthen our business relationship that has recently been established and perhaps develop successful new businesses by fully utilising both of our strengths in the future,” he said.
Datuk Zulkarnain says the export of Sinovac COVID-19 vaccines gives confidence to Pharmaniaga to further explore similar opportunities in other South East Asia (SEA) neighbouring countries and also the African countries.
